학술논문
Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial
Document Type
Article
Author
André, Fabrice; Hee Park, Yeon; Kim, Sung-Bae; Takano, Toshimi; Im, Seock-Ah; Borges, Giuliano; Lima, Joao Paulo; Aksoy, Sercan; Gavila Gregori, Joaquin; De Laurentiis, Michelino; Bianchini, Giampaolo; Roylance, Rebecca; Miyoshi, Yasuo; Armstrong, Anne; Sinha, Rajni; Ruiz Borrego, Manuel; Lim, Elgene; Ettl, Johannes; Yerushalmi, Rinat; Zagouri, Flora; Duhoux, Francois P; Fehm, Tanja; Gambhire, Dhiraj; Cathcart, Jillian; Wu, Cai; Chu, Changan; Egorov, Anton; Krop, Ian
Source
In The Lancet 27 May-2 June 2023 401(10390):1773-1785
Subject
Language
ISSN
0140-6736